Author

Tadhg Guerin

Observed names: Guerin, Tadhg, T Guerin

Observed institution: Novartis (Ireland)

ORCID: 0000-0002-2201-2075

Observed ORCID: 0000-0002-2201-2075

OpenAlex ID: A5055312302

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

2018 · Kenneth R. Chapman, John R. Hurst, et al. · American Journal of Respiratory and Critical Care Medicine · 253

Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema

2017 · Bianca S Gerendas, Sonja Prager, et al. · British Journal of Ophthalmology · 94

Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure

2020 · Gerasimos Filippatos, Christiane E. Angermann, et al. · JAMA Cardiology · 93

PDF

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

2018 · Pablo Altman, Luis Wehbe, et al. · BMC Pulmonary Medicine · 70

PDF

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema

2018 · Sonja G. Karst, Gabor G. Deak, et al. · JAMA Ophthalmology · 35

PDF

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

2018 · Kanji Takahashi, Masahito Ohji, et al. · Clinical ophthalmology · 20

Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA

2019 · Adnan Tufail, Philippe Margaron, et al. · British Journal of Ophthalmology · 17

PDF

Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ)

2025 · Horacio Kaufmann, Jose-Alberto Palma, et al. · Clinical Autonomic Research · 5

PDF

Patient perception of Breezhaler® and Ellipta® device feedback mechanisms in COPD: The ADVANTAGE Study

2018 · Pablo Altman, Miguel A. Bergna, et al. · Current Medical Research and Opinion · 5

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

2023 · S Schreiber, W Reinisch, et al. · Journal of Crohn s and Colitis · 4

PDF

Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics

2021 · Nathan Pfeifer, Tadhg Guerin, et al. · European Respiratory Journal · 4

Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study

2018 · John R. Hurst, Konstantinos Kostikas, et al. · European Respiratory Journal · 2

P288 Copd patients with varying severity of airflow limitation achieve highest peak inspiratory flow rate via the breezhaler® inhaler compared to the ellipta® or the handihaler® dry powder inhalers

2016 · P Goyal, L Wehbe, et al. · Thorax · 1

PDF

Tu1447: IZENCITINIB INDUCTION TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

2022 · Silvio Danese, William J. Sandborn, et al. · Gastroenterology

P221 Comparing the perception of feed-back mechanism of the breezhaler® device with the ellipta® device in patients with chronic obstructive pulmonary disease (COPD): the advantage study

2016 · P Altman, MA Bergna, et al. · Thorax

PDF

Iconographies supplémentaires de l'article : Faisabilité d’un dépistage de la BPCO aux urgences

2012 · M Vial, Peter Apelt, et al.

Works count: 19

Citation count: 604

H-index: 7

I10-index: 7